Concepedia

Xichun Hu

XH

Statistics

Publications

44

Citations

3.2K

H-Index

24

Active since

2007

Affiliations

Fudan University Shanghai Cancer Center(Current)

Shanghai Medical College of Fudan University

Harbin Medical University

Third Affiliated Hospital of Harbin Medical University

Peking University

Xichun Hu is an author at Fudan University Shanghai Cancer Center specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2007–2025

44

Publications

44

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell et al. · New England Journal of Medicine · 2023 · 704 citations · Full text

, , +16

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 393 citations

, , +16

Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

Feng‐Hua Wang, Xiaoli Wei, Jifeng Feng et al. · Journal of Clinical Oncology · 2021 · 351 citations · Full text

, , +17

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Fei Ma, Quchang Ouyang, Wěi Li et al. · Journal of Clinical Oncology · 2019 · 345 citations

, , +17

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

, , +17

1–5 of 44